Ferdinando Pucci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ferdinando Pucci has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Natalie Claudio
Department of Otolaryngology – Head and Neck Surgery, Oregon Health & Science University, Portland, Oregon
47 shared publications - Adrian Wanner
Paul Scherrer Institute PSI Center for Life Sciences, Villigen, Switzerland
46 shared publications - My-Tien Nguyen
Ariadne.ai (Germany) GmbH, Heidelberg, Germany
46 shared publications - Ernesto Satoshi Nakayasu
Biological Sciences Division, Pacific Northwest National Laboratory
13 shared publications - Jennifer M. Finan
Department of Surgery, Oregon Health & Science University, Portland, OR, USA
13 shared publications - Tahereh Ziglari
Department of Otolaryngology – Head and Neck Surgery, Oregon Health and Science University, Portland, Oregon
13 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data and legends from Senescent Cell–Derived Extracellular Vesicles Inhibit Cancer Recurrence by Coordinating Immune Surveillance
Supplementary Data and legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data and legends from Senescent Cell–Derived Extracellular Vesicles Inhibit Cancer Recurrence by Coordinating Immune Surveillance
Supplementary Data and legends
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Senescent Cell–Derived Extracellular Vesicles Inhibit Cancer Recurrence by Coordinating Immune Surveillance
Senescence is a nonproliferative survival state that cancer cells can enter to escape therapy. In addition to soluble factors, senescence cells secrete extracellular vesicles (EV), which are important mediators of intercellular communication. To explore the role of senescent cell (SC)–derived EVs (senEV) in inflammatory responses to senescence, we developed an engraftment-based senescence model in wild-type mice and genetically blocked senEV release in vivo, without significantly affecting soluble mediators. SenEVs were both necessary and sufficient to trigger immune-mediated clearance of SCs, thereby suppressing tumor growth. In the absence of senEVs, the recruitment of MHC-II+ antigen-presenting cells (APC) to the senescence microenvironment was markedly impaired. Blocking senEV release redirected the primary target of SC signaling from APCs to neutrophils. Comprehensive transcriptional and proteomic analyses identified six ligands specific to senEVs, highlighting their role in promoting APC–T cell adhesion and synapse formation. APCs activated CCR2+CD4+ TH17 cells, which seemed to inhibit B-cell activation, and CD4+ T cells were essential for preventing tumor recurrence. These findings suggest that senEVs complement the activity of secreted inflammatory mediators by recruiting and activating distinct immune cell subsets, thereby enhancing the efficient clearance of SCs. These conclusions may have implications not only for tumor recurrence but also for understanding senescence during de novo carcinogenesis. Consequently, this work could inform the development of early detection strategies for cancer based on the biology of cellular senescence.Significance:Chemotherapy-treated senescent tumor cells release extracellular vesicles that trigger an immune response and suppress tumor recurrence.See related commentary by Almeida and Melo, p. 833
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Senescent Cell–Derived Extracellular Vesicles Inhibit Cancer Recurrence by Coordinating Immune Surveillance
Senescence is a nonproliferative survival state that cancer cells can enter to escape therapy. In addition to soluble factors, senescence cells secrete extracellular vesicles (EV), which are important mediators of intercellular communication. To explore the role of senescent cell (SC)–derived EVs (senEV) in inflammatory responses to senescence, we developed an engraftment-based senescence model in wild-type mice and genetically blocked senEV release in vivo, without significantly affecting soluble mediators. SenEVs were both necessary and sufficient to trigger immune-mediated clearance of SCs, thereby suppressing tumor growth. In the absence of senEVs, the recruitment of MHC-II+ antigen-presenting cells (APC) to the senescence microenvironment was markedly impaired. Blocking senEV release redirected the primary target of SC signaling from APCs to neutrophils. Comprehensive transcriptional and proteomic analyses identified six ligands specific to senEVs, highlighting their role in promoting APC–T cell adhesion and synapse formation. APCs activated CCR2+CD4+ TH17 cells, which seemed to inhibit B-cell activation, and CD4+ T cells were essential for preventing tumor recurrence. These findings suggest that senEVs complement the activity of secreted inflammatory mediators by recruiting and activating distinct immune cell subsets, thereby enhancing the efficient clearance of SCs. These conclusions may have implications not only for tumor recurrence but also for understanding senescence during de novo carcinogenesis. Consequently, this work could inform the development of early detection strategies for cancer based on the biology of cellular senescence.Significance:Chemotherapy-treated senescent tumor cells release extracellular vesicles that trigger an immune response and suppress tumor recurrence.See related commentary by Almeida and Melo, p. 833
- Open Access
- 14 March 2026
- Published by Elsevier in Extracellular Vesicle
- Vol. 7
Advancements in extracellular vesicle research
- 14 March 2026
- Published by Elsevier in Extracellular Vesicle
- Vol. 7
Open AccessAdvancements in extracellular vesicle research